drugset / Trial / NCT00599131
Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to learn how to identify early which patients will respond to chemotherapy plus radiation therapy in order to reduce the number of subjects who require surgery (followed by radiation therapy).
Timeline
- Start
- 2007-08
- Primary completion
- 2008-07
- Completion
- 2010-10
Outcome
Outcome not reported
Stopped: “The study was discontinued prematurely due to early stopping rules.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | — |
| Subject | Cisplatin | Other / unclassified | 40 mg/m2 | Intravenous |
| Subject | Cisplatin | Other / unclassified | 100 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 750 mg/m2 | — |